%D9%82%D8%B1%D8%A7%D9%86%DB%8C%D8%B3%D8%AA%D8%B1%D9%88%D9%86GranisetronGranisetron%DA%AF%D8%B1%D8%A7%D9%86%DB%8C%D8%B3%D8%AA%D8%B1%D9%88%D9%86Granis%C3%A9tronGranisetronGraniszetronGranisetron%E3%82%B0%E3%83%A9%E3%83%8B%E3%82%BB%E3%83%88%E3%83%AD%E3%83%B3GranisetronaGranisetronGranisetron%D0%93%D1%80%D0%B0%D0%BD%D1%96%D1%81%D0%B5%D1%82%D1%80%D0%BE%D0%BDQ596708
about
sameAs
Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer PatientsR-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaEffect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy SubjectsPh 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyPh3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapySancuso® for Gastroparesis: An Open Label Study.The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in SubjectsSafety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and VomitingThe Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental SituationsAn Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal GranisetronLerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I SeminomaDrugs to Reduce the Side Effects of ChemotherapyEffect of Granisetron on Morphine Induced Pruritus in Cesarean SectionComp Granisetron Midazolam Comb in Lap ChildrenOral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic ChemoradiationA Phase I Study of the Effects of APF530 Exposure, Granisetron and MoxifloxacinGranisetron Versus Ondansetron: Comparative Effects on ECG, QTcPharmacogenomics and Post-Operative Nausea and VomitingEffect of Granisetron on Usage of Sympathomimetics During Caesarean SectionAdjunctive Granisetron Therapy in Patients With Sepsis or Septic ShockPh3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (2012-02-29)Ultrasound Assessment of the Effect of Metoclopramide Versus Granisetron on Gastric Volume in Patients Undergoing Caesarean SectionStaccato® Granisetron Multiple Dose PK
P4844
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study.Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetronControl of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimensGranisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.Palonosetron and granisetron in postoperative nausea vomiting: A randomized double-blind prospective study.Carbon monoxide contributes to the constipating effects of granisetron in rat colon.Influence of Polymorphisms in the HTR3A and HTR3B Genes on Experimental Pain and the Effect of the 5-HT3 Antagonist GranisetronSimultaneous Determination of Dexamethasone, Ondansetron, Granisetron, Tropisetron, and Azasetron in Infusion Samples by HPLC with DAD Detection.Granisetron versus Granisetron-Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Pediatric Strabismus Surgery: A Randomized Double-Blind Trial.Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy.Symptomatic Improvement of Gastroparesis with Granisetron Transdermal SystemSelective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.Granisetron and carvedilol can protect experimental rats againstadjuvant-induced arthritis.Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.Synthesis and Pharmacological Evaluation of [11C]Granisetron and [18F]Fluoropalonosetron as PET Probes for 5-HT3 Receptor Imaging.A CASE OF GRANISETRON ASSOCIATED INTRAOPERATIVE CARDIAC ARREST.Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.Expression of Concern: “Prevention of Nausea and Vomiting After Middle Ear Surgery: Granisetron Versus Ramosetron,” “Prevention of Vomiting After Tonsillectomy in Children: Granisetron Versus Ramosetron,” and “Granisetron, Droperidol, and MRetraction notice. Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in childrenThe clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist
P921
Q61921034-2F87EACD-AA58-420E-8792-E2C39D89B54BQ61921040-D88777AF-E282-4D34-9D92-2C23D89B7FCDQ61938427-3736C154-57CB-4319-AA6D-2AA5296DFD8CQ61957740-303C6162-5275-4B9E-A5D4-044F783F67E7Q61957742-018FEA4E-1EA4-45A4-9209-501952FAE771Q61970191-8B3A936E-78CF-4A2A-815A-1BFB5A6B4409Q61979084-EFBBD886-F54F-4280-9AC2-BDB4F899A14AQ61980173-06703A10-7CEA-45F1-8D2C-980B94662512Q61980246-A6FBF83A-80C6-438D-95BE-729409B59BFBQ61980778-A638266D-EA40-4680-8505-7BEC8C748707Q62110055-69EC5451-FD78-4781-9661-C49634A0F946Q62110178-8294F10C-F5FF-463B-A13D-2A601B9235B2Q62810142-9ECBC36C-020F-455F-B907-D33EC09A6B50Q62810349-3A94F53A-527A-4379-B5C5-C5D343125666Q63320364-9FBBFD79-80C9-4AB5-8AA7-D87DB1BDDCA2Q63322880-C505DDDF-5B29-4D8A-A85D-E47B7AB0AF76Q63334298-84FAC3F7-FFD1-43EC-912D-E48FBDA4B7FEQ63398324-B9C64F4E-604F-4462-966E-A93A13D2B445Q63535079-3A94A1CC-BAC2-4BAE-A2DF-C958DFE9B59FQ63805747-A2AEB97A-FEE2-435B-8628-8BBCC129C006Q86169868-1AFE068B-CABC-466B-A339-B714EC54E6CEQ87078851-211E9C2D-BF46-4A02-A855-2D9D70D58689Q89153314-1036EC5E-B25D-4ED3-8F10-5AB4021D4558
P4844
Q35208781-C1A374CD-8A2F-4888-B831-BA6FE7F2D743Q36881267-6710D1C2-76C8-491E-AA31-F6280CFB91C8Q36891054-63BB1825-BF7B-43FA-ABCF-F11C5DA7FB9BQ37139336-930C89C8-AC8B-41FE-B3A5-E3C12B6679C2Q37324419-79C362B2-4156-4549-8998-CD91BE20BED1Q37335782-1635CD57-00C2-4CA1-89C9-4E5118FF8035Q37411479-DDFE42DE-E5D1-440E-8A29-6EA99E5F96A7Q37524814-84A888CB-E3DA-4A99-A8C5-B202B05E4CD9Q37607450-F0C70758-E78D-4603-ADF7-997C7875FAD2Q38293050-B942249A-66B5-4B59-B166-21C434339482Q38390738-E2A9FA44-43C0-4ADE-BC9A-E678089C703BQ38405676-280ECE5B-32FF-4B11-BDBB-920A89AE4EC1Q38464109-57DEA106-F22A-4FB3-A302-F4FF1F0DAEE9Q38835521-1933B4E5-72B2-47C6-83D0-781978C3DF6AQ38892469-EE00B0CD-3BDF-43C9-A40E-B19A2321534AQ39028644-65ED8E0C-EB2B-40DD-8E3F-39D442D9E904Q39509848-59DADA4A-55F5-41C2-BDDF-F40832601776Q40060288-A1521D09-5053-480B-886A-F114CA9D5422Q42385651-EE791080-29DD-4B45-82E3-A7ADD168D6C3Q44421662-D0504F84-3013-4D25-95DC-B4EEDBA3B268Q46272601-BCDE5BC6-E9A8-4B8C-B194-84E7305F43F5Q46752788-FAA79EC0-1A64-4906-85FB-80B7D8D7F3C0Q47897593-77A80E30-D12A-4540-90DE-3AB61B92EF35Q48508292-4E3F2DF1-6AC2-4773-BF1D-428997F8D06EQ50879936-C9D911B7-5F28-45B2-8A20-0F3A181315D1Q51347270-7711829C-CA17-4931-A0A1-37FBE6B4FCE8Q61767392-BF1A63F0-FB86-4902-9F1F-FB4601AE73CDQ61767467-23C590A2-D59C-4781-A62C-103AADA18B66Q68478560-13A5E16E-1D58-470C-ABDD-20A771BDF4ED
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Granisetron
@de
Granisetron
@hr
Granisetron
@it
Granisetron
@nl
Granisetron
@sh
Granisetron
@sr
Granisetrona
@pt
Graniszetron
@hu
granisetron
@en
granisétron
@fr
type
label
Granisetron
@de
Granisetron
@hr
Granisetron
@it
Granisetron
@nl
Granisetron
@sh
Granisetron
@sr
Granisetrona
@pt
Graniszetron
@hu
granisetron
@en
granisétron
@fr
altLabel
BRL 43694
@en
BRL-43694
@en
Kytril
@en
LY-278584
@en
SID90340785
@en
Sancuso
@en
prefLabel
Granisetron
@de
Granisetron
@hr
Granisetron
@it
Granisetron
@nl
Granisetron
@sh
Granisetron
@sr
Granisetrona
@pt
Graniszetron
@hu
granisetron
@en
granisétron
@fr
P672
P486
P592
P6366
P646
P665
P683
P1748
P2017
CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=C1C=CC=C4
P2067
312.195011
P2115
N0000021915
P2275
Granisetron
@en